Despite advances in the treatment of retinal diseases with anti-vascular endothelial growth factor therapies, in the real world intravitreal injections remain burdensome and some patients cannot extend their treatment intervals. This symposium explores the latest innovations in continuous drug delivery for the treatment of chronic retinal diseases. It provides an update on the return of the Port Delivery System with ranibizumab (PDS), including ongoing efforts with the Port Delivery Platform, and reviews the latest PDS clinical data for long-term maintenance of vision and retinal anatomy in patients with neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Experts also discuss their experience with the PDS in the clinic and the real world.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.